Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04251169
Title Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (TATEN)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group

Her2-receptor negative breast cancer


Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries ESP

Facility Status City State Zip Country Details
ICO Hospitalet Hospitalet de Llobregat Barcelona Spain Details
Hospital Universitari Vall d'Hebrón Barcelona 08035 Spain Details
Hospital Clinic de Barcelona Barcelona Spain Details
Hospital Universitario 12 de octubre Madrid Spain Details
Hospital Quiron Salud Sagrado Corazon Sevilla Sevilla Spain Details
Fundación Instituto Valenciano de Oncología Valencia 46009 Spain Details
Hospital Clínico Universitario de Valencia Valencia Spain Details
*Shaded cells indicate that there was no data available from for the field